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We analysed the effect of graft-contaminating tumour cells on the long-term survival of 24 patients with high-risk neuroblastoma and
found that patients whose grafts contained detectable neuroblastoma cells had a significantly higher probability of survival than did
patients with no detectable tumour cells. Estimated contamination of the graft by more than 2000 tumour cells was associated with a
significantly higher probability of survival than contamination with fewer tumour cells. We hypothesise that the presence of a critical
number of graft-contaminating neuroblastoma cells can elicit a protective antitumour immune response after autologous
transplantation.
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Induction of a tumour-specific immune response is a major goal in
the treatment of patients with solid tumours (Rosenberg, 2001),
and promising clinical results have been obtained in the case of
some malignancies (Jager et al, 2002). Most vaccination strategies
have been clinically evaluated under conditions of steady-state
haematopoiesis, but not during lymphoid reconstitution. However,
the growth inhibition of sarcoma cells in mice during lymphopenia
induced by sublethal total body irradiation is known for a long
time (Hellstrom et al, 1978). Recently, a specific and long-lasting
antitumour immune response was shown to be induced in RAG1
knockout mice by vaccination during early lymphoid reconstitu-
tion (Hu et al, 2002). In another study, greater activity against
tumours was observed when mice were vaccinated immediately
after myeloablative therapy and autologous bone marrow rescue
(Borrello et al, 2000); similar approaches have been discussed for
humans (Kwak, 1998).
A clinical scenario that most closely mimics those described in
mice is autologous transplantation with a tumour-contaminated
stem cell graft during chemotherapy-induced neutropenia and
lymphopenia. Such a scenario is often encountered in children
with high-risk neuroblastoma, up to 82% of whom have tumour
contamination of their peripheral stem cell grafts (Lode et al, 1997;
Leung et al, 1998; Burchill et al, 2001).
The observations described above suggested to us that the
reinfusion of graft-contaminating tumour cells during chemother-
apy-induced lymphopenia, and the subsequent reconstitution of
lymphopoiesis, might exert a protective effect against relapse. We
therefore retrospectively analysed the long-term survival and
clinical course of 24 children with high-risk neuroblastoma who
underwent autologous transplantation with stem cells purged by
positive selection of CD34
þ cells.
PATIENTS AND METHODS
Stem cell mobilisation and myeloablative therapy
A total of 24 consecutively treated children with high-risk neuro-
blastoma (23 with stage 4 disease and one with stage 3 disease with
N-myc amplification) were included into the retrospective analysis.
In all patients, peripheral blood stem cells (PBSC) were mobilised
and collected as described (Klingebiel et al, 1995). Myeloablative
therapy consisted of melphalan, etoposide, and carboplatin; some
patients also had high-dose mIBG therapy, given as described
(Klingebiel et al, 1998). Of the 24 patients, 21 received post-
transplant immunotherapy with an antibody (ch14.18) to the
tumour-associated disialoganglioside GD2 (Handgretinger et al,
2002). All transplants were given between January 1996 and
February 1998. Median follow-up was 5 years.
Stem cell purging and detection of residual neuroblastoma
cells
The PBSCs of all patients were purged by positive selection of
CD34
þ stem cells by high-gradient magnetic-activated cell sorting
(Handgretinger et al, 1998).The median purity of the CD34
þ stem
cells after positive selection was 97.6%. All 24 CD34
þ stem cell
grafts were examined for the presence of contaminating neuro-
blastoma cells by immunofluorescence with the chimeric anti-GD2
antibody delta ch14.18 (Handgretinger et al, 2002). This technique
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5
normal cells.
Statistical analysis
Distribution of the probability of relapse-free survival was
estimated by the method of Kaplan and Meier (1958). Differences
in the estimated probability of survival were tested by using log-
rank statistics. The number of tumour cells in the grafts of patients
who did and did not experience relapse was compared by using the
Wilcoxon rank-sum test. All tests were two-sided.
RESULTS
The median number of transplanted purified CD34
þ stem cells
was 5.1 10
6kg
 1 body weight (range 0.9–39.8 10
6kg
 1) and
the median to reach 0.5 10
9l
 1 neutrophiles after myeloablative
therapy was 12 days (range 8-24 days). Lymphoid reconstitution
was analysed in eight patients and the median to reach 40.2 10
9
and 41 10
9l
 1 CD3
þ T lymphocytes was 21 days and 6 months,
respectively. Before purging, 17 of 22 grafts tested contained
various numbers of tumour cells (0.82 10
6–5.2 10
6 tumour
cells per graft). Tumour contamination was evaluated in all 24
grafts after purging. Four of the 24 grafts contained measurable
neuroblastoma cells (a total of 2300–74000 neuroblastoma cells
per graft) and all four patients are long-term survivors after
autografting. In contrast, the probability of 5-year survival among
the other 20 patients was 33711% (P¼0.04, log-rank test)
(Figure 1). All deaths in this patient group were caused by relapse.
These data suggest that graft-contaminating tumour cells induced
a protective effect.
In order to estimate whether there would be a threshold number
of protective graft-contaminating tumour cells, we calculated on
the basis of the lower detection limit of our assay (one tumour cell
per 10
5 transplanted mononuclear cells) the possible absolute
number of neuroblastoma cells in the 20 grafts that had no
measurable tumour cells. We assumed maximal contamination
based on our observation of tumour-cell contamination in 17 of
the 22 evaluable unpurged grafts and the fact that more sensitive
methods of tumour detection, such as polymerase chain reaction,
often reveal the presence of tumour cells after purging (Lode et al,
1997; Leung et al, 1998). This estimation showed that survivors
(n¼10) had a significantly larger number of tumour cells in their
grafts than did patients who died of relapse (n¼14) (P¼0.01,
Wilcoxon rank-sum test, Figure 2A). A scatterplot analysis also
revealed a survival discriminant value of approximately 2000
tumour cells (Figure 2A). As shown in Figure 2B, the probability of
5-year survival was 88712% for patients estimated to be infused
with more than 2000 tumour cells (n¼8) but only 19710% for
those estimated to be infused with fewer than 2000 tumour cells
(n¼16) (P¼0.006, log-rank rest). The number of transplanted
CD34
þ stem cells or the remission status at the time of autologous
transplantation had no influence on the outcome (data not shown).
DISCUSSION
Our observations suggest that high-dose chemotherapy followed
by a neuroblastoma-contaminated autograft induces an antineur-
oblastoma effect. The post-transplant lymphopenia induced by
myeloablative chemotherapy and the subsequent homeostasis-
driven proliferation of T cells may favour the induction of a
tumour-specific immune response, as recently observed in mice
(Dummer et al, 2002) and as discussed by Maine and Mule (2002).
In addition, mice vaccinated with modified autologous tumour
cells after transplantation had a higher probability of disease-free
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Figure 1 Kaplan–Meier analysis of the probability of relapse-free survival
after autologous haematopoietic stem cell transplantation with and without
detectable neuroblastoma cells in the graft.
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Figure 2 (A) Scatterplot analysis comparing the estimated absolute
number of neuroblastoma cells in the autografts of patients who did and
did not survive (P¼0.01). (B) Comparison of relapse-free survival of
patients whose autografts were estimated to contain more than 2000 cells
or fewer than 2000 cells (P¼0.006).
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transplantation (Borrello et al, 2000). Moreover, tumour lysate-
pulsed dendritic cells were able to elicit an effective antitumour
immune response during early lymphoid recovery in a murine
weakly immunogenic tumour model (Asavaroengchai et al, 2002).
Altogether these findings suggest that exposure to tumour vaccines
might be effective in inducing antitumour immunity during the
post-transplant period of immune recovery. More recently, a high
response rate has been reported in patients with metastatic
melanoma after a nonmyeloablative lymphodepletion followed by
adoptive transfer of autologous highly selected tumour-reactive
T cells directed against overexpressed self-derived differentiation
antigens (Dudley et al, 2002). The lymphodepletion in this setting
may have led to disruption of homeostatic T-cell regulation or
to abrogation of tolerogenic mechanisms. The reconstitution of
CD3
þ T lymphocytes occurred mainly during the first 6 months
after autografting and is similar to published data on immune
reconstitution after transplantation of highly purified autologous
CD34
þ stem cells (Heitger et al, 1999).
The use of purified CD34
þ stem cells may offer an opportunity
to reshape the repertoire of the reconstituting ‘naı ¨ve’ T lympho-
cytes to include tumour-associated self-antigens, thus overcoming
any tumour-induced suppression of antitumour immunity (Son-
dak et al, 1991).
What could render autologous tumour cells immunogenic in the
post-transplant period? Tumour-associated antigens (TAA), which
are mostly tissue-specific or differentiation antigens encoded by
normal genes (Boon and Old, 1997), are targets for a potential
immune response (Nanda and Sercarz, 1995; Pardoll, 1999). TAAs,
including NY-ESO-1, MAGE-1, and MAGE-3, have been described
in neuroblastoma (Soling et al, 1999). In addition, it is conceivable
that the graft-contaminating neuroblastoma cells are altered
through the freezing and thawing process of the graft, which
might render them immunogenic after infusion into the patient. It
has been shown that cell freezing can induce stress proteins such
as heat-shock proteins (Liu et al, 2000) and that heat-shock
proteins can be bound and processed by dendritic cells (Schild and
Rammensee, 2000). It has also been demonstrated that stressed
apoptotic tumour cells can stimulate dendritic cells and induce
specific cytotoxic T cells (Feng et al, 2002). The post-transplant
treatment with the chimeric antibody ch14.18 may also have
contributed, since antibody-induced apoptosis of neuroblastoma
cells can also promote phagocytosis by dendritic cells and
crosspriming of T cells, as described for an chimeric anti-CD20
antibody (Selenko et al, 2001).
Our observations suggest that graft-contaminating neuroblasto-
ma cells induced a tumour-protective immune response after
transplantation. If so, the initiation of such a response may have
required a threshold quantity of tumour antigen. This would
explain the association between long-term survival and the
presence of more than 2000 estimated tumour cells in the graft.
The reduction of the number of contaminating tumour cells by
CD34
þ cell selection might also play a role in survival by
preventing the infusion of higher numbers of tumour cells that
might overwhelm the immune system and result in relapse
(Brenner et al, 1993). Unfortunately, this retrospective analysis
did not allow us to investigate the expression of potential TAAs by
patients’ tumour cells. Although parts of our clinical observation
were based on an assumption, our findings, taken with those of
other investigators, provide a rationale for future trials in which
autologous grafts of patients with high-risk neuroblastoma or
other tumours are spiked with defined numbers of irradiated
tumour cells or are vaccinated immediately after stem cell
transplantation while still lymphopenic. A thorough analysis of
the expression of potential TAAs by the individual patient’s
tumour cells and an analysis of the post-transplant immune
response should reveal whether this approach results in an
effective and long-lasting tumour protection.
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